Rigel has an exclusive license agreement with Dr. Reddy’s to develop and commercialize REZLIDHIA (olutasidenib) in all potential indications throughout Dr. Reddy’s territory*.
Rigel received an upfront cash payment, and is eligible for regulatory and commercial milestone payments, and tiered royalty payments on net sales of REZLIDHIA in the territory.
*Includes Latin America, South Africa, certain countries in the Commonwealth of Independent States (CIS), India, certain countries in Southeast Asia and North Africa, Australia and New Zealand